Visilizumab
Based on 1 Customer Validation
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.48%
- CAS No.: 219716-33-3
- Masse moléculaire:144.66 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG2 kappa
Human
Visilizumab induces dose- and time-dependent apoptosis of lamina propria T cells. Visilizumab-induces apoptosis of lamina propria T cells is dependent on caspase 3 and 8, but not caspase 9 activation and does not involve the Fas/FasL pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Lamina propria T cells
-
Concentration:1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL
-
Incubation Time:2 hours, 4 hours, 20 hours, 24 hours, 48 hours
-
Result:Induced dose- and time-dependent apoptosis of lamina propria T cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 219716-33-3
-
Appearance Liquid
-
Masse moléculaire 144.66 kDa
-
Color Colorless to light yellow
-
SMILES
[Volociximab]
-
Synonyms
Anti-Human CD3E Recombinant Antibody; HuM291
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (255 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Visilizumab Related Classifications
HY-P99332 Related Classifications
Powered by Bioz